A novel antimicrobial coated non-crosslinked acellular porcine dermal matrix inhibits in vitro Methicillin-resistant Staphylococcus aureus (MRSA) biofilm formation.

Yuri W Novitsky, MD, Ryan A Liese, BS, MBA, Jeffrey R Scott, PhD. University Hospitals Case Medical Center, Brown University, C. R. Bard, Inc. (Davol).

Purpose: The objective of this study was to evaluate the antimicrobial efficacy of a novel antimicrobial (rifampin/minocyline)-coated non-crosslinked acellular porcine dermal matrix device (AM-coated ADM), as compared to Strattice™ Firm, Permacol™, Surgimend™, XCM™ and Bio-A® following static in vitro incubation with clinically-isolated Methicillin-resistant Staphyloccus aureus (MRSA).

Methods: For each device group, six individual 2.2cm diameter disks were die-cut and placed into a 6-well culture plate. A liquid culture of clinically-isolated MRSA (1×106 CFU/ml) was prepared, and 3ml of the resulting inoculum were added to each well. Each plate was then incubated for 24 hours at 37°C.  For each group, three devices were analyzed to quantify total MRSA colony forming units (CFU) per device, and three devices were analyzed by scanning electron microscopy (SEM) to directly visualize biofilm formation.

Results: AM-coated ADM demonstrated complete inhibition of MRSA colonization (0 ± 0 CFU), as compared to colonization of Strattice™ Firm (3.9 x108 ± 1.9 x 107 CFU), Permacol™ (7.8×108 ± 1.7×108 CFU), Surgimend™ (8.9×108 ± 2.9×108 CFU), XCM™ (2.0×108 ± 2.5×107 CFU) and Bio-A® (4.4×108 ± 1.4×107 CFU).  Furthermore, SEM analysis of AM-coated ADM demonstrated no visible MRSA colonies on the device, whereas all other devices evaluated demonstrated robust colonization and biofilm formation.

Conclusions: AM-coated ADM completely inhibited in vitro MRSA device colonization/biofilm formation, as compared to all other devices evaluated.  Data suggest that this novel AM-coated ADM device may provide protection against MRSA biofilm formation.

View Poster

« Return to SAGES 2014 abstract archive